13F Holdings
中文EN

NCNA NuCana plc IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-54.5%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-193.9%
ROA-131.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.5%
Debt / equity0.00x
Current ratio5.60x
Interest coverage-1.59x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-98.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: GBP FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue—————
R&D expense12.74M18.02M25.06M36.43M36.83M
Operating income-20.11M-22.81M-32.78M-39.12M-47.91M
Interest expense12.65M00——
Pretax income-30.52M-22.45M-32.03M-38.45M-47.80M
Income tax-1.17M-3.45M-4.40M-6.43M-7.27M
Net income-29.35M-19.00M-27.63M-32.02M-40.53M
EBITDA-19.84M-22.29M-32.21M-38.39M-46.96M
EPS (basic)0.00-0.26-0.53-0.61-0.78
EPS (diluted)0.00-0.26-0.53-0.61-0.78
Balance sheet
Cash & equivalents24.25M6.75M17.23M41.91M60.26M
Receivables849,000922,0002.67M3.96M4.16M
Current assets26.86M12.27M25.02M54.92M71.61M
PP&E, netmay include right-of-use assets (IFRS)658,000197,000521,000866,000851,000
Intangibles2.20M2.20M2.13M2.37M2.41M
Total assets29.83M14.77M27.81M58.25M77.47M
Current liabilities4.79M8.67M12.68M19.31M11.72M
Total liabilities5.51M8.82M12.92M19.75M11.93M
Shareholders' equity24.33M5.95M14.89M38.50M65.55M
Cash flow statement
Operating cash flow-7.47M-19.12M-26.44M-23.16M-23.82M
Capital expenditure04,0004,00012,00064,000
Free cash flow-7.47M-19.12M-26.44M-23.17M-23.89M
Investing cash flow159,00079,0002.89M120,000-3.56M
Financing cash flow25.01M8.18M-53,000-161,000-98,000
Depreciation & amortization274,000522,000575,000732,000942,000
Stock-based compensation10.03M1.65M3.86M4.89M6.66M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.